Andrew A. Brief, MD North Jersey Orthopedic Specialists Teaneck and Englewood, NJ
A 17 YO healthy male athlete sustained an inversion injury to the foot while competing at varsity level basketball. A physical evaluation by palpation determined tenderness and swelling around the joint, reduced range of motion and pain. X-rays (Figure 1) suggested a Stage 3 medial chondral injury to the talus that was
confirmed by MRI (Figures 2 and 3). Diagnostic arthroscopy confirmed an intact dome of articular cartilage.
Since the patient was approaching the collegiate athletic recruiting season, he was seeking a treatment plan which could expedite his return to competitive play. With the hopes for a faster surgical recovery, the patient enthusiastically embraced the latter surgical option.
Following the manufacturer’s instructions, 60 milliliters of bone marrow was aspirated percutaneously from the anterior superior iliac spine of the pelvis and processed in the SmartPReP 2 BMAC System (HarvestTechnologies, Corp) into 10 mL of Bone Marrow Aspirate Concentrate.
Diagnostic arthroscopy was performed to ensure that the dome of articular cartilage was intact. Subsequently, retrograde drilling of the medial talor dome was performed using a 4.0 mm cannulated drill under direct fluoroscopic guidance. Further debridement of lesion was performed with a spinal curette, followed by a staged delivery of first approximately 3 mL of concentrated stem cells into the cavity of the osteochondral defect (OCD) using a jamshidi needle; this was immediately followed by a graft mix consisting Fig. 1 Fig. 2 Fig. 3 of beta-Tricalcium Phosphate (TCP) and concentrated stem cells placed below the surface of the articular margin. A final AP x-ray showed good consolidation of the lesion consistent with a successful grafting. The patient tolerated the bone marrow aspiration and surgical repair procedure well. Post operative instructions were strict non-weight bearing for 6 weeks with range of motion exercises beginning at 2 weeks and partial weight bearing at 6 weeks post-operative.
The patient was compliant with the 6 weeks of post-operative non-weight bearing. At 8 weeks, x-rays (Figures 4 and 5) showed subchondral lucency consistent with revascularization. Full weight bearing and low impact exercise was initiated at 8 weeks. X-rays at 12 weeks (Figures 6 and 7) showed trabecular filling of the lesion indicative of healing. Patient was able to return to pain-free running at 12 weeks and competitive basketball at 16 weeks.
Because of the high likelihood of failure with non-operative treatment of an OCD of the talus, and given the protracted recovery associated with the standard of care surgical options to date, there exists a need for an alternative approach that is less invasive, requires a shorter recovery period, and is associated with a high
probability of return to pre-injury level of play. Such a modality has been reported in the orthopedic literature for a number of years but has yet 1to be applied for use in the treatment of osteochondral lesions.
After approximately 20 procedures, this author has found that 60 milliliters of bone marrow can be safely and easily harvested percutaneously from the iliac spine in less than 60 seconds. The adjunctive use of concentrated bone marrow stem cell injection carries tremendous promise and the potential for widespread application in the realm of orthopedic trauma surgery and bone healing technology.
With consideration for the Standard of Care approach to treating an OCD of the Talus, this new approach is less invasive, requires less surgical time (avoidance of harvesting autograft), is well tolerated and introduces an enhanced biologic response to healing that may return the patient to normal pain-free activities sooner.
REF: A, A. (2007). Osteochondral Defect repair of the talus using percutaneous delivery of concentrated autologous adult stem cells. North Jersey Orthopedic Specialists Teaneck and Englewood, NJ. [online] Available at: http://www.njorthopaedics.com [Accessed 1 May 2017].
Tags: Macquarie Stem Cells, Dr. Bright, Osteoarthritis Treatment, Dr. Ralph Bright, Stem Cell Therapy, Stem Cell Treatment, Stem Cells for Arthritis